Eclipse Bioinnovations announced it has acquired Terrain Bio, adding AI and machine learning capabilities for RNA sequence design and manufacturing analytics to Eclipsebio’s sequencing-based analytics platform as the company pushes toward a fully integrated workflow for RNA therapeutic development.
The deal brings together Terrain Bio’s machine learning models for RNA sequence optimization, active learning workflows, and an R&D-scale mRNA manufacturing platform with Eclipsebio’s sequencing-derived datasets and quality control tools, including eMERGE™ and eVERSE™. Eclipsebio said the combined offering is intended to connect computational design directly to experimental feedback, enabling an end-to-end Design, Make, Test approach that improves as new development data are generated.
Eclipsebio said the integrated platform will help RNA therapeutic developers iteratively design optimized RNA constructs using AI modeling and active learning, measure structure, translation, and impurities through high-resolution sequencing analytics, and extract actionable insight into manufacturing robustness and quality-by-design.
The company said it will continue supporting existing Terrain Bio customers and will work with partners to ensure a smooth transition following the acquisition.
KEY QUOTES
“This acquisition meaningfully advances our vision for Eclipsebio. Terrain Bio’s proven AI design capabilities strongly complement our sequencing-first analytics, allowing us to support RNA drug developers earlier in development while continuing to deliver the deep sequencing-based validation our partners rely on for confident decision-making.”
Peter Chu, CEO, Eclipsebio
“Eclipsebio’s deep expertise in sequencing-based validation and curated data repository makes this combination uniquely powerful. Together, we close the gap between computational design and real-world experimental validation, helping RNA therapeutics reach the clinic faster and with greater confidence.”
Chetan Tadvalkar, CEO, Terrain Bio
